Equivalent uniform dose, D90, and V100 correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer

Brachytherapy

Volumn 7, Issue 2, 2008, Pages 206-211

  Miles, Edward F ^a   Nelson, John W ^a   Alkaissi, Ali K ^a   Das, Shiva ^a   Clough, Robert W ^a   Anscher, Mitchell S ^a   Oleson, James R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biochemical control; Brachytherapy; Dosimetry; Prostate cancer

Indexed keywords

IODINE 125; PALLADIUM 103;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CHEMICAL ANALYSIS; CONSENSUS; FOLLOW UP; HISTOGRAM; HUMAN; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 41749088230     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.01.002     Document Type: Article

References (33)

1. Lee W.R., Moughan J., Owen J.B., et al. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: A comprehensive survey of prostate brachytherapy in the United States. Cancer 98 (2003) 1987-1994
2. Beyer D.C., Thomas T., Hilbe J., et al. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2 (2003) 77-84
3. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
4. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
5. Kwok Y., DiBiase S.J., Amin P.P., et al. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 53 (2002) 588-594
6. Potters L., Cha C., Oshinsky G., et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 5 (1999) 301-306
7. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
8. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
9. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230
10. Ash D., Al-Qaisieh B., Bottomley D., et al. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol 79 (2006) 185-189
11. 125I low-dose-rate prostate brachytherapy. BJU Int 98 (2006) 1210-1215
12. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
13. Papagikos M.A., Deguzman A.F., Rossi P.J., et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V(100) superior to D(90)?. Brachytherapy 4 (2005) 252-258
14. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
15. Robert Lee W., Deguzman A.F., McMullen K.P., et al. Dosimetry and cancer control after low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 52-59
16. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
17. Willins J., and Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 39 (1997) 347-353
18. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med Phys 26 (1999) 1100
19. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22 (1995) 209-234
20. 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
21. Wu Q., Djajaputra D., Liu H.H., et al. Dose sculpting with generalized equivalent uniform dose. Med Phys 32 (2005) 1387-1396
22. Djajaputra D., and Wu Q. On relating the generalized equivalent uniform dose formalism to the linear-quadratic model. Med Phys 33 (2006) 4481-4489
23. Zhou S.M., Das S., Wang Z., et al. Relationship between the generalized equivalent uniform dose formulation and the Poisson statistics-based tumor control probability model. Med Phys 31 (2004) 2606-2609
24. Zhou S.M., Das S.K., Wang Z., et al. Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys 34 (2007) 2807-2815
25. Li X.A., Wang J.Z., Stewart R.D., et al. Dose escalation in permanent brachytherapy for prostate cancer: Dosimetric and biological considerations. Phys Med Biol 48 (2003) 2753-2765
26. Wang J.Z., and Li X.A. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. Med Phys 30 (2003) 34-40
27. Wang J.Z., Mayr N.A., Nag S., et al. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy. Med Phys 33 (2006) 1025-1032
28. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
29. Cox D.R. Regression models and life-tables. J R Stat Soc B Methodol 34 (1972) 187-220
30. D'Souza W.D., Thames H.D., and Kuban D.A. Dose-volume conundrum for response of prostate cancer to brachytherapy: Summary dosimetric measures and their relationship to tumor control probability. Int J Radiat Oncol Biol Phys 58 (2004) 1540-1548
31. Yu Y. A nondivergent specification of the mean treatment dose in interstitial brachytherapy. Med Phys 23 (1996) 905-909
32. 125I prostate implants. Int J Radiat Oncol Biol Phys 34 (1996) 717-725
33. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943